<scp>Real‐world</scp> experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The <scp>SCHOLAR</scp> ‐2 retrospective chart review study-Reference-Cited by-同舟云学术

Real‐world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR ‐2 retrospective chart review study

Published:2022-10-18 Issue: Volume: Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Hess Georg¹^ORCID,Dreyling Martin²,Oberic Lucie³^ORCID,Gine Eva⁴,Zinzani Pier Luigi⁵^ORCID,Linton Kim⁶,Vilmar Adam⁷,Jerkeman Mats⁸,Chen Jenny M. H.⁹^ORCID,Ohler Anke¹,Stilgenbauer Stephan¹⁰,Thieblemont Catherine¹¹,Lambert Jonathan¹²,Zilioli Vittorio Ruggero¹³,Sancho Juan‐Manuel¹⁴^ORCID,Jiménez‐Ubieto Ana¹⁵,Fischer Luca²,Eyre Toby A.¹⁶^ORCID,Keeping Sam⁹^ORCID,Park Julie E.⁹,Wu James J.¹⁷,Siddiqi Rubina¹⁷,Reitan John¹⁸,Wade Sally¹⁹,Salles Gilles²⁰

Affiliation:

1. Department of Hematology, Oncology and Pneumology, Comprehensive Cancer Center University Medical School of the Johannes Gutenberg‐University Mainz Germany

2. Medizinische Klinik III, LMU Klinikum Munich Germany

3. Service d'Hématologie Toulouse France

4. Department of Hematology, GELTAMO Hospital Clínic of Barcelona Barcelona Spain

5. IRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia ‘Seràgnoli’, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna Bologna Italy

6. The Manchester Cancer Research Center Manchester UK

7. Odense University Hospital Odense Denmark

8. Department of Oncology Skane University Hospital and Lund University Lund Sweden

9. PRECISIONheor Vancouver Canada

10. Department of Internal Medicine III Ulm University Ulm Germany

11. APHP, Hôpital Saint‐Louis, Hemato‐Oncologie Université de Paris Paris France

12. University College London Hospitals NHS Foundation Trust London UK

13. Division of Hematology ASST Grande Ospedale Metropolitano Niguarda Milan Italy

14. GELTAMO, Institut Català d'Oncologia Hospital Germans Trias i Pujol Badalona Spain

15. GELTAMO Hospital Doce de Octubre Madrid Spain

16. Oxford University Hospitals Oxford UK

17. Kite Pharma Santa Monica California USA

18. RJM Group, LLC Crown Point Indiana USA

19. Wade Outcomes Research and Consulting Salt Lake City Utah USA

20. Department of Medicine Memorial Sloan Kettering Cancer Center New York New York USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18519

Reference22 articles.

1. Guideline for the management of mantle cell lymphoma

2. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

3. Review of Bruton Tyrosine Kinase Inhibitors for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

4. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice

5. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dismantling relapsed/refractory mantle cell lymphoma;Blood Reviews;2024-09

2. Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma;Expert Review of Hematology;2024-08-08

3. SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024;Clinical Lymphoma Myeloma and Leukemia;2024-08

4. Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis;Leukemia & Lymphoma;2024-07-08

5. Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas;Frontiers in Oncology;2024-07-01